Imaging Biomarkers in Alzheimer's Disease
暂无分享,去创建一个
[1] B. Barbiroli,et al. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease , 2009, Neurology.
[2] C. DeCarli,et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.
[3] Nick C Fox,et al. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. , 2005, Archives of neurology.
[4] Nick C Fox,et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study , 2003, The Lancet.
[5] R. Schmidt,et al. Comparison of magnetic resonance imaging in Alzheimer's disease, vascular dementia and normal aging. , 1992, European neurology.
[6] Nick C Fox,et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.
[7] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[8] Jeffrey L. Cummings,et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[9] S. Zola-Morgan,et al. Localization of brain function: the legacy of Franz Joseph Gall (1758-1828). , 1995, Annual review of neuroscience.
[10] I. Zerr,et al. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. , 2000, Archives of neurology.
[11] C. Jack,et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.
[12] G. Frisoni,et al. Neuroimaging outcomes in clinical trials in Alzheimer’s disease , 2009, The journal of nutrition, health & aging.
[13] P. Scheltens,et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline , 2007, European journal of neurology.
[14] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[15] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[16] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[17] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[18] R. Mayeux,et al. Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.
[19] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[20] C. Jack,et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. , 2007, Archives of neurology.
[21] C. Jack,et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.
[22] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[23] J. Hodges,et al. Semantic dementia: a unique clinicopathological syndrome , 2007, The Lancet Neurology.
[24] D. Selkoe,et al. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.
[25] B. Miller,et al. CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[26] M. Bobinski,et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease , 1997, Neurobiology of Aging.
[27] D. Loewenstein,et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease , 2008, Neurology.
[28] Nick C Fox,et al. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.
[29] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[30] D. Spencer,et al. Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons , 2003, Neurology.
[31] Nick C Fox,et al. Structural imaging markers for therapeutic trials in Alzheimer’s disease , 2009, The journal of nutrition, health & aging.